PNP inhibitors selectively kill cancer cells lacking SAMHD1

Area of Science:

• Biochemistry
• Molecular Biology
• Immunology

Background:

• Purine nucleoside phosphorylase inhibitors (PNP-Is) are designed to target transformed lymphocytes in leukemia.
• The clinical efficacy of PNP-Is is limited, with only a subset of leukemia patients responding favorably.
• A deeper molecular understanding is needed to explain differential patient responses to PNP-Is.

Purpose of the Study:

• To elucidate the molecular mechanisms underlying differential patient responses to purine nucleoside phosphorylase inhibitors.
• To identify factors that limit the effectiveness of PNP-Is in certain leukemia patients.
• To propose a novel therapeutic strategy based on molecular patient stratification.

Main Methods:

• Investigated the role of deoxyribonucleoside triphosphate (dNTP) hydrolases in cellular responses to PNP inhibition.
• Analyzed the expression and function of SAM and HD domain-containing protein 1 (SAMHD1) in the context of purine metabolism.
• Correlated SAMHD1 activity with dNTP levels and lymphocyte viability under PNP inhibition.

Main Results:

• Identified SAM and HD domain-containing protein 1 (SAMHD1) as a key deoxyribonucleoside triphosphate (dNTP) hydrolase.
• Demonstrated that SAMHD1 prevents the accumulation of toxic dNTP levels during purine nucleoside phosphorylase inhibition.
• Showed that SAMHD1 activity is a critical determinant of cellular sensitivity to PNP-Is.

Conclusions:

• SAMHD1 acts as a molecular brake, preventing dNTP toxicity during PNP inhibition.
• Acquired mutations in SAMHD1 may render leukemia cells susceptible to PNP-Is.
• PNP-Is could be repurposed for targeted therapy in leukemia patients with acquired SAMHD1 mutations.